Table 1:

Clinical trials of the AKT antagonists in combination with other treatment approaches in patients with solid tumors.

Drug	Combination	Tumor type	Outcome	Reference
AZD5363, KI	CT / phase 1	mCRPC	RP2D: 320 mg BID	[152]
Ipatasertib, KI	HAT-abiraterone / phase 2	mCRPC	Superior antitumor activity to HT	[153]
	CT / phase II	mTNBC	Longer PFS	[154]
MK-2206, AI	MEK inhibitor / phase 1	KRAS-mutated solid tumors	Durable response	[134]
	CT / phase 1	advanced solid tumors	Well-tolerated, antitumor activity	[155]
	CT / phase 1	breast cancer	Antitumor activity	[156]
	Anastrozole (aromatase inhibitor) / phase 1	ER+ breast cancer	Well-tolerated	[157]
	Anastrozole (aromatase inhibitor) / phase 2	PIKCA-Mutant ER+/HER2-Breast Cancer	No advantage of the combination	[135]
	Selumetinib (MEK inhibitor)	CRC	No objective response	[136]
Perifosine	RT / phase 1	NSCLC, prostate, oesophageal, colon and bladder cancer	Recommended phase II, 150 mg/day, started one week prior to RT	[141]
	mTOR inhbitior / phase 1	recurrent pediatric solid tumors.	Well-tolerated	[144]
	CT / phase 2	mCRC	Promising clinical activity	[142]
Nelfinavir	RT / Phase 1	rectal cancer	Well tolerated and good tumor regression	[148]
	CRT / Phase 1	rectal cancer	Nelfinavir 750 mg recommended phase II	[149]
	CRT / Phase 1	NSCLC	Acceptable toxicity and promising activity	[150]
	CRT / Phase 1	pancreatic cancer	Acceptable toxicity and promising activity	[151]
	CRT / Phase 2	pancreatic cancer	Acceptable toxicity and promising activity	[147]

CT: chemotherapy CRT: chemoradiotherapy; RT: radiotherapy; HT: hormone therapy; NSCLC: Non-small cell lung cancer; RP2D: recommended phase II dose; mCRPC: metastatic castration resistant prostate cancer; mTNBC: metastatic triple-negative breast cancer; PFS: progression-free survival; KI: kinase inhibitor; AI: allosteric inhibitor; CRC: colorectal cancer; mCRC: metastatic colorectal cancer